

DOVATO IS DESIGNED DIFFERENTLY

– WITH JUST 2 MEDICINES IN A SINGLE TABLET¹

Patient portrayal



WHAT IS DOVATO?

DOVATO contains dolutegravir and lamivudine – it is taken once-daily as a single tablet regimen for people who are new to HIV treatment or switching from their current HIV medicines.¹

HOW IS DOVATO DIFFERENT?

DOVATO is designed differently with just 2 medicines in a single tablet, taken once a day with or without food.¹



No other complete HIV treatment in New Zealand contains fewer medicines in a single tablet than DOVATO.^{1-3,6}



Unlike many HIV treatments that have 3 or 4 medicines, DOVATO has just 2 medicines in a single tablet.^{1-3,6}



DOVATO is proven to effectively help you stay undetectable[†] with fewer medicines in your body.^{1,3-6*}

ASK YOUR DOCTOR IF DOVATO IS RIGHT FOR YOU

Scan the QR code to learn more and access useful resources available on WWW.DOVATO.CO.NZ

Please consult with your doctor or pharmacist before taking DOVATO. Because DOVATO does not cure HIV infection, patients on DOVATO may still develop other infections and illnesses linked to HIV infection. Do not use DOVATO if you are allergic to dolutegravir or lamivudine. Side effects people may experience are headache, nausea, and diarrhoea.¹



Patient portrayal

*As compared with 3- or 4-drug regimens. Based on data from the GEMINI 1 & 2 studies (patients new to treatment) and TANGO study (patients replacing their current HIV treatment). DTG + 3TC was compared with a regimen containing either 3 or 4 medicines, measuring either the percentage of patients with a viral load of <50 copies per mL or the percentage of patients with a viral load of ≥50 copies per mL.^{4,5}

[†]Undetectable means reducing the HIV in your blood to very low levels (<200 copies/mL for >6 months) with ART, which helps prevent sexual transmission of HIV.^{3,6}

Abbreviations: HIV, human immunodeficiency virus; ART, antiretroviral therapy; DTG, dolutegravir; 3TC, lamivudine; NZ, New Zealand

References: 1. GlaxoSmithKline NZ, DOVATO Consumer Medicine Information, 2025. Available at: <https://www.medsafe.govt.nz/consumers/cmi/d/dovato.pdf> (accessed Feb 2026). 2. PHARMAC. Pharmaceutical Schedule, Antiretrovirals. June 2026;v33:1-352. Available at: <https://schedule.pharmac.govt.nz/2026/06/01/Schedule.pdf> (accessed June 2026). 3. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV (updated Sept 2025). 4. Cahn P, et al. *AIDS* 2022;36(1):39-48. 5. Osiyemi O, et al. *Clin Infect Dis* 2022;75(6):975-986. 6. EACS (European AIDS Clinical Society) Guidelines, version 13.0. Available at <https://eacs.sanfordguide.com/en/eacs-hiv/paediatric-hiv-treatment/art-initiation-and-inital-regimen> (accessed March 2026).

Dovato is a film coated tablet containing 50 mg of dolutegravir (as dolutegravir sodium) and 300 mg of lamivudine, which is used for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and adolescents (from 12 years of age weighing at least 40 kg) who have no known or suspected resistance to either antiretroviral component. **Dovato is a Prescription Medicine. Dovato has risks and benefits and should be initiated by a doctor experienced in treating HIV. Dovato is a funded medicine; Special Authority criteria apply. Ask your doctor if Dovato is right for you.** Use strictly as directed. If you have concerns, or side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's consultation fees apply. For more information, you can view the Dovato Consumer Medicine Information at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. Marketed on behalf of ViiV Healthcare by GlaxoSmithKline NZ Limited, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.** Date of Approval: **May 2026** | Date of Expiry: **May 2028** | TAPS-NP24716 | PM-NZ-DLL-PINF-260001

This material is intended for NZ audiences only. Any information provided on this document should be discussed with a healthcare professional and does not replace a healthcare professional's advice.